New Delhi: The Indian Pharmaceutical Market (IPM) in July underwent a value growth of 7.9 per cent driven by new launches in the anti-diabetic segment and value growth of cardiac therapies.
According to a monthly sales tracker PharmaTrac, in July IPM reported total sales of ₹20,404 crore led by a double-digit value and mid-single digit volume growth in cardiac therapy segment.
On a year-on-year (YoY) basis, IPM growth recorded an increase of 1.8 percentage points, from 6.1 per cent. While, sequentially, the market growth remained muted with an marginal decline of 0.1 percentage point.
Meanwhile, for July, volume trends remained stagnant with a marginal uptick of 0.4 per cent.
Among the top performing brands, GlaxoSmithKline, (GSK) popular antibiotic Augmentin reclaimed its top spot with net sales of ₹80 crore at a strong value and volume growth of 10.5 per cent and 10.3 per cent respectively.
On a 12-month basis currently, Augmentin stands as the brand with the highest sales in India, however past few months indicate that the medicine has been consistently reporting a decline in net sales.
Data from the monthly sales tracker suggest that during April to June, the brand reported total sales of ₹170 crore—₹52 crore, ₹52 crore, and ₹66 crore (in increasing order)—down from ₹217 crore (₹70 crore, ₹73 crore, and ₹74 crore) recorded in the preceding three-month period.
According to GSK Indian arm in Q1 (April-June), the company’s general medicines portfolio sales was below anticipated levels, primarily due to seasonal disruption, which affected the overall result.
Besides this, USV’s leading type-2 diabetic therapy Glycomet was replaced by Novo and Abbott penfill insulin brand Human Mixtard–indicated for type-1 diabetes–which reported total sales of ₹74 crore, up against the former ₹71 crore.
However, the therapy stands as the second biggest brand with a moving annual turnover (MAT) of ₹821 crore as of July this year.
According to PharmaTrac, of the total ₹2.3 lakh crore domestic market, cardiac therapies continue to command the highest share with a MAT of ₹31,052 crore followed by gastro–₹28,145 crore and anti-infectives—₹27,000 crore.
Among the top performing brands, GlaxoSmithKline, (GSK) popular antibiotic Augmentin reclaimed its top spot with net sales of ₹80 crore at a strong value and volume growth of 10.5 per cent and 10.3 per cent respectively.
On a 12-month basis currently, Augmentin stands as the brand with the highest sales in India, however past few months indicate that the medicine has been consistently reporting a decline in net sales.
Data from the monthly sales tracker suggest that during April to June, the brand reported total sales of ₹170 crore—₹52 crore, ₹52 crore, and ₹66 crore (in increasing order)—down from ₹217 crore (₹70 crore, ₹73 crore, and ₹74 crore) recorded in the preceding three-month period.
According to GSK Indian arm in Q1 (April-June), the company’s general medicines portfolio sales was below anticipated levels, primarily due to seasonal disruption, which affected the overall result.
Besides this, USV’s leading type-2 diabetic therapy Glycomet was replaced by Novo and Abbott penfill insulin brand Human Mixtard–indicated for type-1 diabetes–which reported total sales of ₹74 crore, up against the former ₹71 crore.
However, the therapy stands as the second biggest brand with a moving annual turnover (MAT) of ₹821 crore as of July this year.
According to PharmaTrac, of the total ₹2.3 lakh crore domestic market, cardiac therapies continue to command the highest share with a MAT of ₹31,052 crore followed by gastro–₹28,145 crore and anti-infectives—₹27,000 crore.
Notably driven by new launches anti-diabetic market underwent a value growth of 9.2 per cent to ₹20,949 crore.
Over the IPM future outlook, while presenting the tracker data at a virtual call, Sheetal Sapale, VP Commercial, Pharmarack said, “the disease landscape is changing and moving forward, biosimilars will change the outlook of the Indian market.”
